Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 128 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seasonal Allergic Rhinitis Clear all
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

NCT00163514
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
58
States / cities
Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00719862
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo nasal spray, 0.15% azelastine hydrochloride Nasal Spray
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older · Female only
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
34
States / cities
Huntington Beach, California • Long Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00651118
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, azelastine Hcl, azelastineHcl / fluticasone propionate, fluticasone propionate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
43
States / cities
Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

NCT00807053
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Ciclesonide HFA, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
31
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

NCT00929968
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, VAK694, Fluticasone
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nasal Ocular Reflexes Contribute to Eye Symptoms

NCT00117832
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Azelastine nasal spray
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

NCT01916226
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and Seasonal
Interventions
FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis

NCT00789555
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Olopatadine hydrochloride 0.6% nasal spray (PATANASE), Olopatadine nasal spray vehicle, pH 3.7, Olopatadine nasal spray vehicle, pH 7.0
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 2, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional

Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

NCT00318747
View directory record Official record
Conditions
Asthma, Allergy, Allergic Rhinitis, Rhinitis, Allergic, Seasonal
Interventions
Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

NCT01578278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

NCT04709575
View directory record Official record
Conditions
Allergic Rhinitis, Conjunctivitis
Interventions
REGN5713, REGN5714, REGN5715, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
14
States / cities
Bangor, Maine • Baltimore, Maryland • Plymouth, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

NCT01458275
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
66
States / cities
Little Rock, Arkansas • Baldwin Park, California • Costa Mesa, California + 49 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

NCT02402465
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, Fluticasone propionate, Fluticasone/Azelastine nasal spray, Nasal Allergen Challenge
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 4 Interventional

Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen

NCT00638118
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
15 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 2, 2026, 6:42 AM EDT
Completed No phase listed Observational

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

NCT00985075
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00824473
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, 0.15% azelastine hydrochloride
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 1 Interventional

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

NCT02557633
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Neptune City, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 2 Interventional

The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis

NCT00917020
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Nasal CO2, Inactive Placebo Gas
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 3 Interventional

A Trial of Grazax in Subjects With Hayfever

NCT00421655
View directory record Official record
Conditions
Allergy
Interventions
Grazax
Drug
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 3 Interventional

Trial of STAHIST in Seasonal Allergic Rhinitis

NCT01293201
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
STAHIST, Placebo
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Stockbridge, Georgia • South Bend, Indiana • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 3 Interventional

Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action

NCT00118729
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
GW685698X Aqueous Nasal Spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Woodstock, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

NCT00502775
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
fluticasone furoate, fexofenadine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
42
States / cities
Little Rock, Arkansas • Albany, Georgia • Columbus, Georgia + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 2, 2026, 6:42 AM EDT
Recruiting Not applicable Interventional

Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis

NCT07588672
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis
Interventions
PL-14 Allergy Blocker, Ayr® Saline Nasal Mist
Device
Lead sponsor
Polyrizon Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Normal, Illinois • St Louis, Missouri • Ocean City, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 2, 2026, 6:42 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

NCT00305487
View directory record Official record
Conditions
Hay Fever, Seasonal Allergic Rhinitis
Interventions
Ciclesonide nasal spray
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
71
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Costa Mesa, California + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 2, 2026, 6:42 AM EDT